Hematologist-Oncologist: Wang, MD | Loyola Medicine

Coronavirus 2019 (COVID-19) Update

Loyola Medicine hospitals are prepared to provide appropriate care for the safety and well-being of our community. Learn more here.

Wang, MD

Medicine

Hematology/Oncology
Assistant Professor

Languages Spoken

English

Clinical Expertise

  • Head And Neck Cancer
  • Lung Cancer

About Dr. Wang

Interests

Medical Education

Medical School
University of Iowa
Residency
St. Mary Medical Center - Internal Medicine
Loyola University Medical Center - Internal Medicine
Fellowship
  • Loyola University Medical Center/Oncology Institute - Hematology & Medical Oncology

Board Certification

American Board of Internal Medicine
American Board of Internal Medicine Subspecialty Medical Oncology

Research

  • Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T; Wagner, CR; Scurti, GM; Hutchens, KA; Godellas, C; Clark, AL; Kolawole, EM; Hellman, LM; Singh, NK; Huyke, FA; Wang, SY; Calabrese, KM; Embree, HD; Orentas, R; Shirai, K; Dellacecca, E; Garrett-Mayer, E; Li, M; Eby, JM; Stiff, PJ; Evavold, BD; Baker, BM; Le Poole, IC; Dropulic, B; Clark, JI; Nishimura, MI, Cancer immunology, immunotherapy : CII
  • Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T; Wagner, CR; Scurti, GM; Hutchens, KA; Godellas, C; Clark, AL; Kolawole, EM; Hellman, LM; Singh, NK; Huyke, FA; Wang, SY; Calabrese, KM; Embree, HD; Orentas, R; Shirai, K; Dellacecca, E; Garrett-Mayer, E; Li, M; Eby, JM; Stiff, PJ; Evavold, BD; Baker, BM; Le Poole, IC; Dropulic, B; Clark, JI; Nishimura, MI, Cancer immunology, immunotherapy : CII
  • Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. Wang, SY; Cowan, JE; Cary, KC; Chan, JM; Carroll, PR; Cooperberg, MR, BJU international
View All ResearchShow Less
  • miR-19 miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance., Wang, SY; Shiboski, S; Belair, CD; Cooperberg, MR; Simko, JP; Stoppler, H; Cowan, J; Carroll, PR; Blelloch, R, PLoS ONE